Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Celtic Pharma's Therapy for Brain Tumor-Associated Cerebral Edema Is Better in Patients with Metastatic Disease

Phase III study, however, did not meet overall primary endpoint of reducing dependency on standard-of-care within five weeks to 50%.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »